Board of Directors
Clinical Trials conducted to date
Systemic Lupus Erythematosus
News & Media
Investor and Media Contact
Leading ovarian cancer expert Dr Andrew Stephens appointed to Invion’s advisory board
Invion secures research alliance with Hudson Institute of Medical Research
Change of registered office and principal place of business
Invion is a life sciences company focussed on the development of treatments for major opportunities in inflammatory diseases. Invion is an ASX listed company (ASX:IVX), with operations in Brisbane, Australia and Delaware, USA.
Invion has an agreement to conduct clinical development of Photosoft™ globally, with The Cho Group will providing non-dilutive funding for R&D and clinical trials as part of a global development strategy. Invion has been granted exclusivity in Australia and New Zealand to commercialise and distribute Photosoft™ for the treatment of cancers.